Commentary on the WHO classification of tumors of lymphoid tissues (2008): Aggressive B-cell lymphomas

Journal of Hematopathology

Volumn 2, Issue 2, 2009, Pages 83-87

  Balague Ponz, Olga ^a   Ott, German ^b   Hasserjian, Robert P ^c   Elenitoba Johnson, Kojo S J ^d   de Leval, Laurence ^e   de Jong, Daphne ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Classification; Clinico pathological entity; Diffuse large B cell lymphoma; EBV; Immunodeficiency; WHO

Indexed keywords

EID: 78649692217     PISSN: None     EISSN: 18655785     Source Type: Journal    
DOI: 10.1007/s12308-009-0038-8     Document Type: Article

References (15)

1. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of tumors of hematopoietic and lymphoid tissues. IARC, Lyon
2. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
3. Yamaguchi M, Seto M, Okamoto M et al (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815-821
4. Yamaguchi M, Nakamura N, Suzuki R et al (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopatho-logical review in 120 patients. Haematologica 93:1195-1202
5. De JD, Xie W, Rosenwald A et al (2009) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 62:128-138
6. Booman M, Douwes J, Glas AM et al (2006) Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-Cell lymphoma. Clin Cancer Res 12:2698-2705
7. Kuppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3:801-812
8. Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74:9964-9971
9. Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412
10. Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136
11. Oksenhendler E, Boulanger E, Galicier L et al (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multi-centric Castleman disease. Blood 99:2331-2336
12. Colomo L, Loong F, Rives S et al (2004) Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28:736-747
13. Gaidano G, Cerri M, Capello D et al (2002) Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol 119:622-628
14. Kanno H, Ohsawa M, Hashimoto M et al (1999) HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas. Int J Cancer 82:630-634
15. Mauray S, Fuzzati-Armentero MT, Trouillet P et al (2000) Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 30:2065-2073